First Bank & Trust Increases Position in Maximus, Inc. (MMS)
First Bank & Trust increased its stake in shares of Maximus, Inc. (NYSE:MMS) by 4.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,507 shares of the health services provider’s stock after buying an additional 101 shares during the period. First Bank & Trust’s holdings in Maximus were worth $157,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the stock. Shell Asset Management Co. bought a new stake in shares of Maximus during the first quarter valued at about $542,000. Glen Harbor Capital Management LLC boosted its stake in shares of Maximus by 1.9% in the first quarter. Glen Harbor Capital Management LLC now owns 2,332 shares of the health services provider’s stock valued at $145,000 after buying an additional 44 shares in the last quarter. Meritage Portfolio Management bought a new stake in shares of Maximus during the first quarter valued at about $5,668,000. Nationwide Fund Advisors boosted its stake in shares of Maximus by 16.9% in the first quarter. Nationwide Fund Advisors now owns 357,173 shares of the health services provider’s stock valued at $22,216,000 after buying an additional 51,639 shares in the last quarter. Finally, Navellier & Associates Inc boosted its stake in shares of Maximus by 10.9% in the first quarter. Navellier & Associates Inc now owns 8,737 shares of the health services provider’s stock valued at $543,000 after buying an additional 856 shares in the last quarter. 97.89% of the stock is owned by institutional investors.
Maximus, Inc. (MMS) opened at 61.50 on Tuesday. Maximus, Inc. has a 12-month low of $43.69 and a 12-month high of $64.97. The firm has a market cap of $3.99 billion, a price-to-earnings ratio of 20.16 and a beta of 1.39. The company’s 50 day moving average is $61.91 and its 200 day moving average is $60.73.
Maximus (NYSE:MMS) last released its quarterly earnings data on Thursday, August 3rd. The health services provider reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.03. The firm had revenue of $600.40 million for the quarter, compared to analyst estimates of $614.12 million. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.79 EPS. On average, equities analysts anticipate that Maximus, Inc. will post $3.09 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th will be paid a $0.045 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $0.18 annualized dividend and a yield of 0.29%. Maximus’s dividend payout ratio is presently 5.73%.
COPYRIGHT VIOLATION WARNING: “First Bank & Trust Increases Position in Maximus, Inc. (MMS)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/08/first-bank-trust-increases-position-in-maximus-inc-mms.html.
Several brokerages have recently issued reports on MMS. KeyCorp reissued a “sector weight” rating on shares of Maximus in a research note on Thursday, May 25th. ValuEngine cut shares of Maximus from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Canaccord Genuity cut shares of Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective for the company. in a research note on Tuesday, July 4th. BidaskClub cut shares of Maximus from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Zacks Investment Research raised shares of Maximus from a “sell” rating to a “hold” rating in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $62.17.
In other Maximus news, President Bruce Caswell sold 17,197 shares of the company’s stock in a transaction that occurred on Thursday, May 11th. The shares were sold at an average price of $62.47, for a total value of $1,074,296.59. Following the transaction, the president now owns 27,904 shares in the company, valued at approximately $1,743,162.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Richard A. Montoni sold 30,000 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $62.81, for a total transaction of $1,884,300.00. Following the transaction, the chief executive officer now owns 584,114 shares in the company, valued at approximately $36,688,200.34. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,636 shares of company stock worth $6,874,122. Company insiders own 3.10% of the company’s stock.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maximus, Inc. (NYSE:MMS).
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.